Table I.
Demographics and baseline characteristics—subjects with no family history of atopy (asthma, atopic dermatitis, or allergic rhinitis) or food allergies
| Palivizumab treated |
Palivizumab untreated |
Palivizumab untreated non-RSV hospitalized |
|
|---|---|---|---|
| Variable | (n = 101) | (n = 100) | (n = 75§) |
| Mean birth weight (kg) ± SD (range) | 1.36 ± 0.45 (0.7-2.5) | 1.60 ± 0.47‡ (0.6-2.7) | 1.55 ± 0.45† (0.6-2.7) |
| Mean gestational age (wk) ± SD (range) | 29.9 ± 2.36 (25-34) | 31.5 ± 2.58‡ (24-35) | 31.3 ± 2.63‡ (24-35) |
| Female sex (%) | 43.6 | 49.0 | 52.0 |
| White race (%) | 97.0 | 95.0 | 96.0 |
| Multiple birth (%) | 17.8 | 34.0† | 30.7∗ |
| Mean enrollment age (mo) ± SD (range) | 19.4 ± 7.46 (5-40) | 20.5 ± 9.45 (1-37) | 20.1 ± 9.63 (1-37) |
| Mean enrollment weight (kg) ± SD (range) | 10.26 ± 1.95 (4.9-16.2) | 10.23 ± 2.78 (3.1-16.5) | 10.00 ± 2.70 (3.1-16.5) |
| Breast-fed (%) | 55.4 | 51.0 | 52.0 |
| Mean no. of siblings ± SD (range) | 0.7 ± 0.78 (0-3) | 1.2 ± 1.04‡ (0-4) | 1.1 ± 1.01∗ (0-4) |
| Siblings in day care (%) | 28.7 | 37.0 | 38.7 |
| Subject in day care (%) | 24.8 | 17.0 | 18.7 |
| Smokers in home (%) | 49.5 | 57.0 | 60.0 |
| Caregiver smokes (%) | 27.7 | 28.0 | 33.3 |
| Pets in home (%) | 37.6 | 27.0 | 30.7 |
| Wood-burning stove (%) | 16.8 | 15.0 | 20.0 |
| RSV antibody (% <2log2) | 47.0 | 30.3∗ | 39.2 |
| IgE antibody (% <5 IU/mL) | 59.6 | 49.5 | 48.6 |
∗
P ≤ .050.
†
P ≤ .010.
‡
P ≤ .001 for comparison with palivizumab-treated group.
§
The 75 children were a subgroup of the 100 untreated subjects.